2022
DOI: 10.3389/fmolb.2022.1083225
|View full text |Cite
|
Sign up to set email alerts
|

Small-molecule compound from AlphaScreen disrupts tau-glycan interface

Abstract: Tauopathies are neurodegenerative diseases characterized by intracellular abnormal tau deposits in the brain. Tau aggregates can propagate from one neuron to another in a prion-like manner, mediated by the interaction between tau and cell surface heparan sulfate proteoglycans. We developed an AlphaScreen assay, with His-tagged tau and biotinylated heparin, to represent the tau-HS interface to target the tau-glycan interface. Using our AlphaScreen assay, with a Z-factor of 0.65, we screened ∼300 compounds and d… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 29 publications
0
1
0
Order By: Relevance
“…So, development of a sensitive homogeneous immunoassay has been the goal of numerous research efforts. 11 So far, some similar methods have been developed, including latex agglutination tests, 12,13 enzyme channelling immunoassay, 14 luminescent oxygen channelling immunoassay (LOCI), 15,16 AlphaScreen, 17 etc. However, few of the methods have been used for POCT.…”
Section: Introductionmentioning
confidence: 99%
“…So, development of a sensitive homogeneous immunoassay has been the goal of numerous research efforts. 11 So far, some similar methods have been developed, including latex agglutination tests, 12,13 enzyme channelling immunoassay, 14 luminescent oxygen channelling immunoassay (LOCI), 15,16 AlphaScreen, 17 etc. However, few of the methods have been used for POCT.…”
Section: Introductionmentioning
confidence: 99%